Clinical Trial Update: Study of Dasatinib in Patients With Chronic Phase Chronic Myeloid Leukemia and a Suboptimal Response to Imatinib [Phase 2]

View source ↗

Summary

Phase 2 trial of dasatinib in patients with chronic phase chronic myeloid leukemia who had suboptimal responses to imatinib; the study was terminated but result…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia

Drugs mentioned

• Sprycel (dasatinib)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Leukemia, Myeloid, Chronic | Phase 2 | Status: TERMINATED | Results posted: 2011-07-07